Sec. 5.3. Subject to federal law and consistent with standard medical practices in opioid treatment for substance abuse, the division shall adopt rules under IC 4-22-2 concerning opioid treatment by an opioid treatment provider, including the following:

(1) A requirement that the opioid treatment provider periodically review with the patient the patient’s treatment plan. In the review, the opioid treatment provider shall consider changes to the plan with the goal of requiring the minimal clinically necessary medication dose, including, when appropriate, the goal of opioid abstinence.

(2) Treatment protocols containing best practice guidelines for the treatment of opiate dependent patients, including the following:

(A) Appropriate clinical use of all drugs approved by the federal Food and Drug Administration for the treatment of opioid addiction, including the following when available:

(i) Opioid maintenance.

(ii) Detoxification.

(iii) Overdose reversal.

(iv) Relapse prevention.

(v) Long acting, nonaddictive medication assisted treatment medications.

(B) Requirement of initial and periodic behavioral health assessments for each patient.

(C) Appropriate use of providing overdose reversal, relapse prevention, counseling, and ancillary services.

(D) Transitioning off agonist and partial agonist therapies with the goal, when appropriate, of opioid abstinence.

(E) Training and experience requirements for providers who treat and manage opiate dependent patients.

(F) Requirement that a provider who prescribes opioid medication for a patient periodically review INSPECT (as defined in IC 25-26-24-7) concerning controlled substance information for the patient.

As added by P.L.8-2016, SEC.4. Amended by P.L.51-2019, SEC.1.